As the House Select Committee investigates GenScript’s alleged ties to China, U.S. biopharma companies and Chinese contract development and manufacturing organizations (CDMOs) face mounting pressure under the BIOSECURE Act. This development poses significant challenges for public relations and investor relations teams in the industry.
The BIOSECURE Act, aimed at safeguarding American bioeconomy from foreign threats, has led to increased scrutiny of partnerships between U.S. firms and Chinese entities. The recent request by the House Select Committee for an FBI briefing on GenScript’s links to China underscores the growing concern over potential national security risks.
As more companies come under the radar, effective communication strategies will be crucial in managing investor concerns and maintaining public trust. PR and IR professionals must navigate this complex landscape, balancing transparency with the need to protect sensitive information and business relationships.
